The European Medicines Agency’s CHMP recommended eight new medicines in its September agenda, including Novo Nordisk’s preventive hemophilia A therapy and multiple oncology and dermatology options. The list also included two ovarian cancer therapies, plus a potential first oral treatment for hidradenitis suppurativa. CHMP opinions are not final authorizations but drive the pathway to an EU Commission decision. In addition to new therapies, the CHMP recommendations included label expansions, reflecting continued EU-level updates across established products and emerging indications. For biotech and pharma, the September CHMP batch highlights the continued emphasis on expanding treatment modalities beyond injectables, with the oral hidradenitis suppurativa option standing out in the recommendations. Companies and developers with assets in parallel EU filings will track the timing and committee language closely as it can influence how dossiers respond to concerns during the final authorization step.